Clinical Trials Logo

Clinical Trial Summary

This is a randomized, parallel, double-blind clinical trial. The main objective is to compare the efficacy of resistance training based on power training, multimodal exercise with non-specific exercises and a control group on functionality and body composition in women over 65 years of age with pre-sarcopenia. The intervention in both groups will be carried out for 30 weeks, with three weekly sessions. Two evaluations will be performed, one pre-intervention and one post-intervention. Functionality (Timed Up & Go test (TUG), chair stand test and hand grip test and Short Physical Performance Battery (SPPB)), body composition (Body fat %, skeletal muscle index (SMI), appendicular skeletal muscle (ASM), waist circumference, waist hip ratio, body weight, body mass index (BMI)) will be evaluated.


Clinical Trial Description

Design: Randomized, controlled clinical trial with three parallel groups, in which women over 65 years of age will be recruited. Study participants will be assigned to one of the three interventions. The study will have a duration of 8 months. There will be 2 evaluation visits, an initial one, a final one at 8 months. During 8 months there will be 3 weekly sessions lasting 50 minutes. Scope: The study will be carried out in the Salamanca Health Area, in collaboration with the Research, Teaching and Assistance Unit of the Faculty of Nursing and Physiotherapy of the University of Salamanca and the Department of Elderly People of the Salamanca City Council. Interventions: 1) Multimodal Exercise Group (GEM); 2) Muscle Power Exercise Group (GEP); 3) No Exercise Control Group (CG). The GEM and GEP sessions follow the same structural pattern. They will be structured according to the recommendations of the American College of Sports Medicine (ACSM). In the main part of the GEP, strength exercises will be performed and the speed will be progressively increased until the exercises are performed at the maximum speed that each participant can do. Study population: 104 subjects over 65 years of age from the city of Salamanca will be included, distributed in 3 groups at a 1:1:1 ratio. Randomization will be performed using the Epidat 4.2 program. The sample size was calculated using GRANMO Version 7. 12 April 2012. The main study variables are: Functionality (Timed Up & Go test (TUG), chair stand test and hand grip test and Short Physical Performance Battery (SPPB)), body composition (Body fat %, skeletal muscle index (SMI), appendicular skeletal muscle (ASM), waist circumference, waist hip ratio, body weight, body mass index (BMI)), SARC-F Questionnaire, % RM estimated by force-velocity profile and Gait speed. Population characteristics will be presented as mean and standard deviation for continuous variables and as frequency distribution for qualitative variables. Statistical analysis The effect of the intervention on the study variables if the variables are parametric, Student's t-test will be used, and if they are non-parametric, the Wilcoxon test will be used. An alpha risk of 0.05 is set as the limit of statistical significance. The statistical program to be used will be SPSS, v.26.0. The study will be carried out with the authorization of the Ethics Committee on Drug Research (CEIm) of the Salamanca Health Area, and with the prior informed consent of the study subjects. The participants will be informed of the objectives of the project and of the risks and benefits of the examinations and interventions to be performed. The study has been designed and subsequently assessed in accordance with Law 14/2007 on Biomedical Research, the ethical principles of the Declaration of Helsinki of the World Medical Association on ethical principles for medical research involving human subjects, as well as the other ethical principles and legal regulations applicable according to the characteristics of the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05870046
Study type Interventional
Source University of Salamanca
Contact
Status Active, not recruiting
Phase N/A
Start date February 15, 2024
Completion date February 28, 2025

See also
  Status Clinical Trial Phase
Completed NCT05059964 - Circuit Training and Aerobic Exercise Among Sedentary Elderly Population N/A
Recruiting NCT04091152 - TIKeasy TAblet satisfaCtion (TikTac)
Recruiting NCT04938349 - Dual Task Perturbation Training for OAwMCI N/A
Completed NCT04983602 - Physiotherapy Led Community Intervention for Older Adults Discharged From the Emergency Department N/A
Recruiting NCT04851405 - Implementing an Evidence-based Exercise Program to Reduce Falls in Community-dwelling Older Adults (Otago) N/A
Completed NCT04757454 - Performance Indicators of the SARC-F Questionnaire in Acute Care
Recruiting NCT06388434 - Protective Arm Balance Responses N/A
Recruiting NCT04301713 - Multifactorial Study of the Relationship Between the Conditions of Life and the Incidence of Risk of Falling
Recruiting NCT04715581 - Multicomponent Prehabilitation and Outcomes in Elderly Patients With Frailty N/A
Completed NCT04297111 - Probiotic-Muscle Study N/A
Completed NCT04165005 - Mindfulness-based Short Intervention for Seniors - Decentering Effects on Cognitive Functions and Psychological Distress N/A
Completed NCT03134807 - The Very Old Intensive Care Patient: A Multinational Prospective Observation Study
Completed NCT05287932 - Brief Physical Activity Intervention for Older People With Multimorbidity N/A
Completed NCT04770259 - Pre-surgical Protocol for Frail Elderly People in Order to Reduce Hospitalization Days (APOPM). N/A
Not yet recruiting NCT06352099 - Dietary Supplementation and Cognitive Functions in the Elderly N/A
Not yet recruiting NCT04348539 - Older People Gait: Physiomechanics and Functionality N/A
Recruiting NCT04856202 - ACP in Older Patients With Multimorbidity: a Randomized Pilot N/A
Not yet recruiting NCT06353438 - Hydraulic Resistance and Older Adults N/A
Not yet recruiting NCT05317338 - Multicomponent Exercises in Functional Performance and Cognitive Ability of Hospitalized Elderly N/A
Recruiting NCT05175508 - Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Phase 2/Phase 3